fda decision on tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide Wins FDA Approval for
Description
Non-GLP-1 weight loss medications offer alternatives for patients who cannot tolerate GLP-1 agents or require different mechanisms of action
Retatrutide dosing from TRIUMPH-1: 2mg4mg8mg12mg escalation chart with exact syringe units
Personalized skincare education and guided access to licensed peptide therapy through EllieMD
PlexusDx explores the safety, interactions, and personalized approach to using both medications for weight management and mood support
have a BMI of 27 or above and at least one weight-related problem (this could be high blood pressure, heart disease or sleep apnoea)
